Virginia G Kaklamani
Play Video
UT Badge
Accepting new patients

Kaklamani, MD

Rating Rating Rating Rating Rating 4.8
  • Oncologist
Call: 210-450-1143

If you're an existing patient of Dr. Kaklamani, please connect via MyChart




Your location:

About me

About Me

Dr. Virginia G. Kaklamani is a professor of medicine in the division of hematology/oncology at UT Health San Antonio and is the leader of the Breast Cancer Program at UT Health San Antonio MD Anderson Cancer Center. Dr. Kaklamani completed her medical training with honors at the University of Athens and her residency in internal medicine at Newton-Wellesley Hospital in Boston. She completed her fellowship in hematology/oncology at Northwestern University. She also received a master of science degree in clinical investigation from Northwestern University. She was head of the Translational Breast Cancer Program at Northwestern University and co-director of Northwestern's cancer genetics program. Her research interests include studying high-risk families and identifying genetic mutations that are associated with an increased risk for breast, colon and prostate cancer. She has identified several genetic mutations related to obesity that increase the risk of breast cancer. Dr. Kaklamani is a clinical investigator with expertise in designing clinical trials with targeted agents.
San Antonios Top Doctors for Women
Waisbren J., Uthe R., Siziopikou K., Kaklamani V. BRCA 1/2 gene mutation andgastrointestinal stromal tumours: a potential association. BMJ Case Rep. 2015 Jul6;2015. pii: bcr2014208830. doi: 10.1136/bcr-2014-208830. PubMed PMID: 26150619.
Kaklamani V.G., Jeruss J.S., Hughes E., Siziopikou K., Timms K.M., Gutin A., Abkevich V., Sangale Z., Solimeno C., Brown K.L., Jones J., Hartman A.R., Meservey C., Jovanovic B., Helenowski I., Khan S.A., Bethke K., Hansen N., Uthe R., Giordano S., Rosen S., Hoskins K., Von Roenn J., Jain S., Parini V., Gradishar W. Phase II neoadjuvant clinicaltrial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579). Breast Cancer Res Treat. 2015 Jun;151(3):629-38. doi: 10.1007/s10549-015-3435-y. Epub 2015 May 26. PubMed PMID: 26006067.
Daly M.B., Pilarski R., Axilbund J.E., Buys S.S., Crawford B., Friedman S., Garber J.E., Horton C., Kaklamani V., Klein C., Kohlmann W., Kurian A., Litton J., Madlensky L., Marcom P.K., Merajver S.D., Offit K., Pal T., Pasche B., Reiser G., Shannon K.M., Swisher E., Voian N.C., Weitzel J.N., Whelan A., Wiesner G.L., Dwyer M.A., Kumar R.; National comprehensive cancer network. Genetic/familial high-risk assessment: breast and ovarian, version 1.2014. J Natl Compr Canc Netw. 2014 Sep;12(9):1326-38. PubMed PMID: 25190698.




English, Greek


  • Award
  • Award
  • Award
  • Award
  • Award



Medical School:
National & Kapodistrian University of Athens

Newton-Wellesley Hospital


Board Certification:
American Board of Internal Medicine/Medical Oncology